Shaun Marcus

Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel.

Friction Control Solutions, Inc. develops and manufactures polymer based devices. It provides significant added value services to the automotive, aerospace and energy industries. The company was founded by Amir Weisberg, Boris Shamshidov and Alexander Ignatovsky in 2003 and headquartered in Farmington Hills, MI.

DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany.